(-)-11-hydroxy-δ8-THC-d3 (exempt preparation) (Synonyms: (-)-11-hydroxy-δ8-Tetrahydrocannabinol-d3,(-)-trans-δ8-THC-d3,7-hydroxy-δ6-THC-d3) |
| Catalog No.GC91736 |
(−)-11-hydroxy-Δ8-THC-d3 (exempt preparation) is intended for use as an internal standard for the quantification of (−)-11-hydroxy-Δ8-THC by GC- or LC-MS.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(−)-11-hydroxy-Δ8-THC-d3 (exempt preparation) is intended for use as an internal standard for the quantification of (−)-11-hydroxy-Δ8-THC by GC- or LC-MS. (−)-11-hydroxy-Δ8-THC is categorized as a phytocannabinoid metabolite.[1],[2] (–)-11-hydroxy-Δ8-THC is a metabolite of Δ8-THC . It has analgesic activity in mice. (–)-11-hydroxy-Δ8-THC-d3 is regulated as a Schedule I compound in the United States. (−)-11-hydroxy-Δ8-THC-d3 (exempt preparation) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.
References:
[1].Watanabe, K., Yamamoto, I., Oguri, K., et al.Comparison in mice of pharmacological effects of Δ8-tetrahydrocannabinol and its metabolites oxidized at 11-positionEur. J. Pharm.63(1)1-6(1980).
[2].Rhee, M.H., Vogel, Z., Barg, J., et al.Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclaseJ. Med. Chem.40(20)3228-3233(1997).
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *